Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 8/20 | 0.64 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 2/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 3/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31332020 | 0.90 | HTR2A (0.51) | HTR2AAOC3HTR6SIGMAR1BCHE | |
| SCHEMBL27366016 | 0.90 | HTR2A (0.51) | HTR2AAOC3HTR6SIGMAR1BCHE | |
| SCHEMBL27366009 | 0.86 | BCHE (0.48) | HTR2AAOC3HTR6SIGMAR1BCHE | |
| SCHEMBL27365914 | 0.86 | HTR2A (0.61) | HTR2AAOC3HTR6 | |
| SCHEMBL31331965 | 0.86 | HTR2A (0.61) | HTR2AAOC3HTR6 | |
| SCHEMBL6601575 | 0.82 | AOC3 (0.67) | HTR2AAOC3SIGMAR1BCHECHRM2 | |
| SCHEMBL31332092 | 0.82 | BCHE (0.49) | HTR2AAOC3BCHEHTR2B | |
| SCHEMBL27366592 | 0.82 | BCHE (0.49) | HTR2AAOC3BCHEHTR2B | |
| SCHEMBL31332123 | 0.81 | HTR2A (0.65) | HTR2AAOC3HTR6SIGMAR1BCHE | |
| SCHEMBL27366100 | 0.81 | HTR2A (0.65) | HTR2AAOC3HTR6SIGMAR1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333371-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2025-10-30 | — | — | US | disclosed |
| EP-4532462-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2025-04-09 | — | — | EP | disclosed |
| WO-2023230649-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2023-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250333371-A1 | COMPOUNDS | SDHA, PYGB, SLC18A2 | HTR2A 225/4885AOC3 703/4885HTR6 187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.